Back to Search Start Over

Human papillomavirus-related oropharyngeal carcinoma.

Authors :
Saito Y
Homma A
Kiyota N
Tahara M
Hanai N
Asakage T
Matsuura K
Ota I
Yokota T
Sano D
Kodaira T
Motegi A
Yasuda K
Takahashi S
Tanaka K
Onoe T
Okano S
Imamura Y
Ariizumi Y
Hayashi R
Source :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2022 Jul 08; Vol. 52 (7), pp. 700-706.
Publication Year :
2022

Abstract

It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with clinical presentations different from nonrelated head and neck carcinoma. Twenty years after and with the revision of the tumor-node-metastasis classification in 2017, various clinical trials focused on human papillomavirus-related oropharyngeal carcinoma to improve the prognosis and quality of life of patients with this disease. However, the incidence of human papillomavirus-related cancers is increasing, which is expected to be particularly prominent in Japan, where human papillomavirus vaccination is not widely available. In this review, we describe the current status of clinical trials (mainly focused on initial surgery and radiation dose reduction) for, primary and secondary prevention of, and the present status of human papillomavirus-related oropharyngeal carcinoma in Japan.<br /> (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1465-3621
Volume :
52
Issue :
7
Database :
MEDLINE
Journal :
Japanese journal of clinical oncology
Publication Type :
Academic Journal
Accession number :
35383359
Full Text :
https://doi.org/10.1093/jjco/hyac049